Edison Pharmaceuticals, Inc. Closes Financing
Capital Directed to EPI-A0001 and EPI-743 Approval Trials
MOUNTAIN VIEW, Calif., Sept. 13, 2011 /PRNewswire/ -- Edison Pharmaceuticals, Inc. announced today that it has closed a Series E Preferred Financing. Capital raised will fund US and European approval trials for the company's clinical candidates, EPI-A0001 and EPI-743. Terms of the financing were not disclosed.
Edison Pharmaceuticals is a patient- and physician-founded company devoted to developing new medicines to transform the lives of children and adults diagnosed with rare and neglected diseases. Currently, the company is focused on inherited mitochondrial diseases for which there are no approved drugs. These conditions are life-threatening and highly debilitating. Edison's specialized skill set spans the discovery, development, and translation of redox-based drugs.
SOURCE Edison Pharmaceuticals, Inc.
More by this Source
Edison Pharmaceuticals, Inc. signs licensing agreement with Dainippon Sumitomo Pharma Co., Ltd. for development & commercialization of orphan mitochondrial and adult central nervous system disease drugs
Mar 28, 2013, 08:55 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.